

COPY OF PAPERS ORIGINALLY FILED

PATENT

Case Docket No. MVIEWM.005A
Date: March 5, 2002

Page 1

In re application of

Sherman, et al.

App. No.

09/501,730

Filed

February 10, 2000

For

AGGREGATE-FREE URATE

OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC

POLYMER CONJUGATES

Examiner

Pak, Yong D.

Art Unit

1652

UNITED STATES PATENT AND TRADEMARK OFFICE

P.O. Box 2327

Arlington, VA 22202

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: United States Patent and Trademark Office, P.O. 2327, Arlington, VA 22202, on

> March 5, 2002 (Date)

Dale C. Hunt, Reg. No. 41,857

RECEIVED

MAR 1 4 2002

TECH CENTER 1600/2900

Sir:

Transmitted herewith is an Amendment in the above-identified application.

No fees are due as shown below:

CLAIMS AS FILED						
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL. FEE
Total Claims	23		33	= 0 ×	\$9	= \$0
Independent Claims	0		3	= 0 ×	\$42	= \$0
If application has been amended to contain multiple dependent claim(s), then add \$140					\$140	= \$0
Time Extension Fee						\$0
				TOTAL ADDITIONAL FEE FOR THIS AMENDMENT		\$0

Also enclosed is:

- (X) Six (6) sheets of formal drawings.
- (X) The present application qualifies for small entity status under 37 C.F.R. § 1.27.

Case Docket No. MVIEWM.005A

Date: March 5, 2002

Page 2

- (X) Return prepaid postcard.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Dale C. Hunt

Registration No. 41,857 Attorney of Record



COPY OF PAPERS ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Sherman, et al.

Appl. No. : 09/501,730

Filed : February 10, 2000

For : AGGREGATE-FREE URATE

OXIDASE FOR PREPARATION OF NON-

IMMUNOGENIC POLYMER

CONJUGATES

Examiner : Pak, Yong D.

Group Art Unit 1652

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, United States Patent and Trademark Office, P.O. Box 2327, Arlington VA, 22202, on

March 5, 2002

Dale C. Hunt, Reg. No. 41,857

RECEIVED

MAR 1 4 2002

TECH CENTER 1600/2900

RESPONSE TO OFFICE ACTION

Assistant Commission of Patents United States Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Dear Sir:

In response to the Office Action mailed December 5, 2001, in the above-captioned case, Applicants respectfully request consideration of the following remarks.

Remarks

Claims 1-33 are currently pending, of which Claims 1-10, 17-28, and 33 are being examined and Claims 11-16 and 29-32 have been withdrawn without prejudice. Claims 1-10, 17-28, and 33 were rejected in the Office Action.

Rejections under 35 U.S.C. §102(b)

R&D Focus News Reference

Claims 1-8, 17-28, and 33 are rejected under 35 U.S.C. §102(b) as being anticipated by R&D Focus Drug News of August 24, 1998. According to the Office Action, the R&D Focus News reference teaches a PEGylated recombinant uricase and "[b]ecause the referenced uricase